Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israel-based company, for the month of May 2022. The filing reports on a specific corporate event announced via press release on May 25, 2022.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the period. The only specific financial figure disclosed is a non-dilutive grant of approximately $1.2 million awarded for the year 2022.
Material Changes
The primary material event is the selection of the Company's ongoing sepsis clinical program by the Israel Innovation Authority to receive a third non-dilutive grant. This represents a significant milestone in the Company's clinical development funding.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the announcement of the grant. The grant is described as non-dilutive, indicating it will not require the issuance of new equity.
Key Facts for Investor Verification
- The Israel Innovation Authority awarded a third non-dilutive grant of approximately $1.2 million for 2022.
- The funding is specifically designated for the Company's ongoing sepsis clinical program.
- The grant is non-dilutive, meaning it does not impact existing shareholder equity.
- No other financial performance data or operational metrics are included in this specific filing.